Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced initial clinical data from its Phase 1 monotherapy trial of ZN-c3, a WEE1 inhibitor targeting advanced solid tumors. The data will be presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, scheduled for April 10-15 and May 17-21. ZN-c3 aims to induce DNA damage in cancer cells, promoting cell death and tumor regression. Currently, Zentalis is also conducting a Phase 1b trial combining ZN-c3 with chemotherapy and plans to initiate a Phase 2 trial for uterine serous carcinoma by year-end.
- Initial clinical data for ZN-c3 to be presented at AACR Annual Meeting 2021.
- ZN-c3 is in development for advanced solid tumors and shows potential for efficacy.
- Clinical trials may face delays or adverse effects, influenced by COVID-19.
- Company has significant financial losses and needs additional funding.
NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 1/2 monotherapy trial of ZN-c3, the Company’s WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021. AACR is being held April 10-15 and May 17-21.
About ZN-c3
ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with advanced solid tumors and expects to report data from the Phase 1 portion at the AACR Annual Meeting 2021. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer, with plans to initiate a Phase 2 trial investigating ZN-c3 as a monotherapy in patients with uterine serous carcinoma in 2021.
About Zentalis
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the development, potential, safety, efficacy, and regulatory and clinical progress of our product candidates in the Unites States and globally, plans and timing for the initiation of and the release of data from our clinical trials, including the presentation of initial clinical data from the Phase 1 portion of our Phase 1/2 clinical trial of ZN-c3 at AACR Annual Meeting 2021, and our ability to meet other key milestones, the anticipated direct and indirect impact of COVID-19 on our business and operations, and the sufficiency of our cash and cash equivalents. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the outbreak of the novel coronavirus disease, COVID-19, has adversely impacted and may continue to adversely impact our business, including our preclinical studies and clinical trials; our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of our lead product candidate; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Investor Contact:
Thomas Hoffmann
Solebury Trout
1.646.378.2931
thoffmann@soleburytrout.com
Media Contact:
Julia Deutsch
Solebury Trout
1.646.378.2967
jdeutsch@soleburytrout.com
FAQ
What is ZN-c3 and its purpose?
When will the initial clinical data for ZN-c3 be available?
What are Zentalis Pharmaceuticals' next steps for ZN-c3?
How might COVID-19 affect Zentalis Pharmaceuticals' operations?
What are the financial challenges facing Zentalis Pharmaceuticals?
